How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

40,880 results for

Dementia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Dementia: assessment, management and support for people living with dementia and their carers

Dementia: assessment, management and support for people living with dementia and their carers Dementia: assessment, management and Dementia: assessment, management and support for people living with dementia support for people living with dementia and their carers and their carers NICE guideline Published: 20 June 2018 nice.org.uk/guidance/ng97 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility (...) , to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dementia: assessment, management and support for people living with dementia and their carers

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a primary care setting. (PubMed)

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a primary care setting. Alzheimer's disease and other forms of dementia are becoming increasingly common with the aging of most populations. The majority of individuals with dementia will first present for care and assessment in primary care settings. There is a need for brief dementia screening instruments that can accurately diagnose dementia in primary care settings. The Mini-Cog is a brief, cognitive (...) screening test that is frequently used to evaluate cognition in older adults in various settings.To determine the diagnostic accuracy of the Mini-Cog for diagnosing Alzheimer's disease dementia and related dementias in a primary care setting.We searched the Cochrane Dementia and Cognitive Improvement Register of Diagnostic Test Accuracy Studies, MEDLINE, Embase and four other databases, initially to September 2012. Since then, four updates to the search were performed using the same search methods

Full Text available with Trip Pro

2018 Cochrane

3. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). (PubMed)

18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 18F-florbetaben uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-florbetaben. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18F-florbetaben

Full Text available with Trip Pro

2017 Cochrane

4. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). (PubMed)

18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 18F-flutemetamol uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and the confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-flutemetamol. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18F-flutemetamol

2017 Cochrane

5. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). (PubMed)

18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 18F-florbetapir uptake by brain tissue measured by positron emission tomography (PET) is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology in an established (...) dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using amyloid biomarkers tests like 18F-florbetapir. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18F-florbetapir to predict

Full Text available with Trip Pro

2017 Cochrane

6. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). (PubMed)

CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Research suggests that measurable change in cerebrospinal fluid (CSF) biomarkers occurs years in advance of the onset of clinical symptoms (Beckett 2010). In this review, we aimed to assess the ability of CSF tau biomarkers (t-tau and p-tau) and the CSF tau (t-tau or p-tau)/ABeta ratio to enable the detection of Alzheimer's disease pathology (...) in patients with mild cognitive impairment (MCI). These biomarkers have been proposed as important in new criteria for Alzheimer's disease dementia that incorporate biomarker abnormalities.To determine the diagnostic accuracy of 1) CSF t-tau, 2) CSF p-tau, 3) the CSF t-tau/ABeta ratio and 4) the CSF p-tau/ABeta ratio index tests for detecting people with MCI at baseline who would clinically convert to Alzheimer's disease dementia or other forms of dementia at follow-up.The most recent search

Full Text available with Trip Pro

2017 Cochrane

7. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem)

Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

Full Text available with Trip Pro

2016 NIHR HTA programme

8. The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives

The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross sectional study of 60-89 year old people with dementia and qualitative exploration of individual, carer and professional perspectives Journals Library An error occurred retrieving

Full Text available with Trip Pro

2016 NIHR HTA programme

9. Improving care for people with dementia: development and initial feasibility study for evaluation of life story work in dementia care

Improving care for people with dementia: development and initial feasibility study for evaluation of life story work in dementia care Improving care for people with dementia: development and initial feasibility study for evaluation of life story work in dementia care Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try

Full Text available with Trip Pro

2016 NIHR HTA programme

10. The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives

The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives The Prevalence of Visual Impairment in People (...) with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives Bowen M, Edgar DF, Hancock B, Haque S, Shah R, Buchanan S, Iliffe S, Maskell S, Pickett J, Taylor J-P, O'leary N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bowen M

2016 Health Technology Assessment (HTA) Database.

11. Improving care for people with dementia: development and initial feasibility study for evaluation of life story work in dementia care

Improving care for people with dementia: development and initial feasibility study for evaluation of life story work in dementia care Improving care for people with dementia: development and initial feasibility study for evaluation of life story work in dementia care Improving care for people with dementia: development and initial feasibility study for evaluation of life story work in dementia care Gridley K, Brooks J, Birks Y, Baxter K, Parker G. Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gridley K, Brooks J, Birks Y, Baxter K, Parker G.. Improving care for people with dementia: development and initial feasibility study for evaluation of life story work in dementia care. Health Services and Delivery Research 2016; 4(23) Authors' objectives To establish whether or not full evaluation of Life story work (LSW) was feasible. Improving

2016 Health Technology Assessment (HTA) Database.

12. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem)

Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Bunn F, Burn A-M, Goodman C, Robinson L, Rait G, Norton S, Bennett H, Poole M, Schoeman J, Brayne C Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bunn F, Burn A-M, Goodman C, Robinson L, Rait G, Norton S, Bennett H, Poole M, Schoeman J, Brayne C. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Health Services and Delivery Research 2016; 4(8) Authors' objectives To explore the impact of dementia on access to non-dementia services and identify ways of improving

2016 Health Technology Assessment (HTA) Database.

13. Computerised cognitive training for preventing dementia in people with mild cognitive impairment. (PubMed)

Computerised cognitive training for preventing dementia in people with mild cognitive impairment. The number of people living with dementia is increasing rapidly. Clinical dementia does not develop suddenly, but rather is preceded by a period of cognitive decline beyond normal age-related change. People at this intermediate stage between normal cognitive function and clinical dementia are often described as having mild cognitive impairment (MCI). Considerable research and clinical efforts have (...) been directed toward finding disease-modifying interventions that may prevent or delay progression from MCI to clinical dementia.To evaluate the effects of at least 12 weeks of computerised cognitive training (CCT) on maintaining or improving cognitive function and preventing dementia in people with mild cognitive impairment.We searched to 31 May 2018 in ALOIS (www.medicine.ox.ac.uk/alois) and ran additional searches in MEDLINE, Embase, PsycINFO, CINAHL, ClinicalTrials.gov, and the WHO portal/ICTRP

2019 Cochrane

14. AD-8 for detection of dementia across a variety of healthcare settings. (PubMed)

AD-8 for detection of dementia across a variety of healthcare settings. Dementia assessment often involves initial screening, using a brief tool, followed by more detailed assessment where required. The AD-8 is a short questionnaire, completed by a suitable 'informant' who knows the person well. AD-8 is designed to assess change in functional performance secondary to cognitive change.To determine the diagnostic accuracy of the informant-based AD-8 questionnaire, in detection of all-cause (...) (undifferentiated) dementia in adults. Where data were available, we described the following: the diagnostic accuracy of the AD-8 at various predefined threshold scores; the diagnostic accuracy of the AD-8 for each healthcare setting and the effects of heterogeneity on the reported diagnostic accuracy of the AD-8.We searched the following sources on 27 May 2014, with an update to 7 June 2018: ALOIS (Cochrane Dementia and Cognitive Improvement Group), MEDLINE (Ovid SP), Embase (Ovid SP), PsycINFO (Ovid SP

2019 Cochrane

15. Cognitive training for people with mild to moderate dementia. (PubMed)

Cognitive training for people with mild to moderate dementia. Cognitive impairment, a defining feature of dementia, plays an important role in the compromised functional independence that characterises the condition. Cognitive training (CT) is an approach that uses guided practice on structured tasks with the direct aim of improving or maintaining cognitive abilities.• To assess effects of CT on cognitive and non-cognitive outcomes for people with mild to moderate dementia and their caregivers (...) .• To compare effects of CT with those of other non-pharmacological interventions, including cognitive stimulation or rehabilitation, for people with mild to moderate dementia and their caregivers.• To identify and explore factors related to intervention and trial design that may be associated with the efficacy of CT for people with mild to moderate dementia and their caregivers.We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group Specialised Register, on 5 July 2018. ALOIS contains

2019 Cochrane

16. A scoping review of behaviour change theories in adults without dementia to adapt and develop the 'PHYT in dementia', a model promoting physical activity in people with dementia. (PubMed)

A scoping review of behaviour change theories in adults without dementia to adapt and develop the 'PHYT in dementia', a model promoting physical activity in people with dementia. Research has established that exercise and physical activity can improve executive functioning, independence and quality of life in people with dementia. A dedicated theory explaining behaviour change in relation to physical activity in people with dementia does not exist. We aimed to develop a theoretical model which (...) can be used to inform effective interventions to promote physical activity in people with dementia.There were five phases: 1. A search of the literature to identify theories which have been used to explain behaviour change in relation to physical activity in adult populations without a diagnosis of dementia; 2. Description of the theories (and sub-theories) and their main constructs; 3. Synthesis of the constructs; 4. Adaptation of the constructs to dementia; 5. Development and explanation

2019 Maturitas

17. Diagnosis of dementia in the elderly with PTSD

Diagnosis of dementia in the elderly with PTSD Diagnosis of dementia in the elderly with PTSD We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Diagnosis of dementia in the elderly with PTSD Share: Reading time less than 1 minute Some of the symptoms of posttraumatic stress disorder (PTSD) remind of the symptoms of early development of dementia (...) . This can make it difficult with an assessment tool to clearly see if a person diagnosed with PTSD has started to develop dementia. Question Is there scientific evidence for any assessment tool that can identify development of dementia in the elderly with PTSD? SBU Enquiry Service consists of systematic literature searches to highlight studies that can address questions received by the SBU Enquiry Service from Swedish healthcare or social service providers. Relevant references are compiled by an SBU

2018 Swedish Council on Technology Assessement

18. Dementia

Dementia Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history

2018 Trip Evidence Maps

19. Traumatic Brain Injury and Dementia

Traumatic Brain Injury and Dementia 4 February 2019 Prepared for: Department of Veterans Affairs Veterans Health Administration Health Services Research & Development Service Washington, DC 20420 Prepared by: Evidence Synthesis Program (ESP) Coordinating Center Portland VA Health Care System Portland, OR Mark Helfand, MD, MPH, MS, Director Evidence Brief: Traumatic Brain Injury and Dementia Authors: Kim Peterson, MS Stephanie Veazie, MPH Donald Bourne, MPH Johanna Anderson, MPH Evidence (...) Synthesis Program 4 Evidence Brief: TBI and Dementia Evidence Synthesis Program i PREFACE The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. These reports help: · Develop clinical policies informed by evidence; · Implement effective services to improve patient outcomes and to support VA clinical practice

2019 Veterans Affairs Evidence-based Synthesis Program Reports

20. France has delisted anti-dementia agents

France has delisted anti-dementia agents MED CHECK - TIP December 2018/ Vol.4 No.12 · Page 29 -The Informed Prescriber C N o 12 M ED HECK D e ce m b e r 2 0 1 8 Dying Cochrane: Could it be resuscitated? Herpes zoster subunit vaccine Shingrix: Baloxavir (Xofluza®) for Influenza: No Value No difference from Tamiflu in efficacy, and suppresses immunity Cochrane review on HPV vaccine should be revised: Due to missing trials, adjuvant toxicity, mortality and healthy user bias Editorial Dying

2019 Med Check - The Informed Prescriber

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>